The use of inhaled corticosteroids in chronically ventilated preterm infants

Seminars in Fetal and Neonatal Medicine

Volumn 22, Issue 5, 2017, Pages 296-301

  Nelin, Leif D ^a   Logan, J Wells ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Bronchopulmonary dysplasia; Mechanical ventilation; Neonatal intensive care; Prematurity; Pulmonary function

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; STEROID; GLUCOCORTICOID;

AEROSOL; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BODY GROWTH; CARDIOMYOPATHY; CLINICAL OUTCOME; DIGESTIVE SYSTEM PERFORATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LUNG DYSPLASIA; MENTAL DISEASE; PREMATURITY; REVIEW; INHALATIONAL DRUG ADMINISTRATION; NEWBORN;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; RESPIRATION, ARTIFICIAL;

EID: 85026406288     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2017.07.005     Document Type: Review

References (60)

1. McEvoy, C.T., Jain, L., Schmidt, B., Abman, S., Bancalari, E., Aschner, J.L., Bronchopulmonary dysplasia: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc 11:Suppl 3 (2014), S146–S153.
2. Stoll, B.J., Hansen, N.I., Bell, E.F., Walsh, M.C., Carlo, W.A., Shankaran, S., et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA 314 (2015), 1039–1051.
3. Doyle, L.W., Respiratory function at age 8–9 years in extremely low birthweight/very preterm children born in Victoria in 1991–1992. Pediatr Pulmonol 41 (2006), 570–576.
4. O'Shea, T.M., Shah, B., Allred, E.N., Fichorova, R.N., Kuban, K.C., Dammann, O., et al. Inflammation-initiating illnesses, inflammation-related proteins, and cognitive impairment in extremely preterm infants. Brain Behav Immun 29 (2013), 104–112.
5. Jobe, A.H., Bancalari, E., Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163 (2001), 1723–1729.
6. Hines, D., Modi, N., Lee, S.K., Isayama, T., Sjörs, G., Gagliardi, L., et al. Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. Acta Paediatr 106 (2017), 366–374.
7. Poindexter, B.B., Feng, R., Schmidt, B., Aschner, J.L., Ballard, R.A., Hamvas, A., et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc 12 (2015), 1822–1830.
8. Isayama, T., Lee, S.K., Yang, J., Lee, D., Daspal, S., Dunn, M., et al. Revisiting the definition of bronchopulmonary dysplasia: effect of changing panoply of respiratory support for preterm neonates. JAMA Pediatr 171 (2017), 271–279.
9. Doyle, L.W., Halliday, H.L., Ehrenkranz, R.A., Davis, P.G., Sinclair, J.C., An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 165 (2014), 1258–1260.
10. Clouse, B.J., Jadcherla, S.R., Slaughter, J.L., Systematic review of inhaled bronchodilator and corticosteroid therapies in infants with bronchopulmonary dysplasia: implications and future directions. PloS One, 11, 2016, e0148188.
11. Shinwell, E.S., Portnov, I., Meerpohl, J.J., Karen, T., Bassler, D., Inhaled corticosteroids for bronchopulmonary dysplasia: A meta-analysis. Pediatrics, 138(6), 2016 pii: e20162511.
12. Jobe, A.H., Mechanisms of lung injury and bronchopulmonary dysplasia. Am J Perinatol 33 (2016), 1076–1078.
13. Van Marter, L.J., Leviton, A., Kuban, K.C., Pagano, M., Allred, E.N., Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics 86 (1990), 331–336.
14. Massaro, G.D., Massaro, D., Formation of pulmonary alveoli and gas-exchange surface area: quantitation and regulation. Annu Rev Physiol 58 (1996), 73–92.
15. Poindexter, B.B., Martin, C.R., Impact of nutrition on bronchopulmonary dysplasia. Clin Perinatol 42 (2015), 797–806.
16. D'Angio, C.T., Ambalavanan, N., Carlo, W.A., McDonald, S.A., Skogstrand, K., Hougaard, D.M., et al. Blood cytokine profiles associated with distinct patterns of bronchopulmonary dysplasia among extremely low birth weight infants. J Pediatr 174 (2016), 45–51.
17. Balena-Borneman, J., Ambalavanan, N., Tiwari, H.K., Griffin, R.L., Halloran, B., Askenazi, D., Biomarkers associated with bronchopulmonary dysplasia/mortality in premature infants. Pediatr Res 81 (2017), 519–525.
18. de Benedictis, F.M., Bush, A., Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 185 (2012), 12–23.
19. Halliday, H.L., The effect of postnatal steroids on growth and development. J Perinat Med 29 (2001), 281–285.
20. Rivera, L., Siddaiah, R., Oji-Mmuo, C., Silveyra, G.R., Silveyra, P., Biomarkers for bronchopulmonary dysplasia in the preterm infant. Front Pediatr, 4, 2016, 33.
21. Baier, R.J., Majid, A., Parupia, H., Loggins, J., Kruger, T.E., CC chemokine concentrations increase in respiratory distress syndrome and correlate with development of bronchopulmonary dysplasia. Pediatr Pulmonol 37 (2004), 137–148.
22. Gupta, G.K., Cole, C.H., Abbasi, S., Demissie, S., Njinimbam, C., Nielsen, H.C., et al. Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol 30 (2000), 275–281.
23. Cazzato, S., Ridolfi, L., Bernardi, F., Faldella, G., Bertelli, L., Lung function outcome at school age in very low birth weight children. Pediatr Pulmonol 48 (2013), 830–837.
24. Malmberg, L.P., Pelkonen, A.S., Malmström, K., Saarinen, K.M., Kajosaari, M., Hakulinen, A., et al. Very low birth weight and respiratory outcome: association between airway inflammation and hyperresponsiveness. Ann Allergy Asthma Immunol 111 (2013), 96–101.
25. Choukroun, M.L., Feghali, H., Vautrat, S., Marquant, F., Nacka, F., Leroy, V., et al. Pulmonary outcome and its correlates in school-aged children born with a gestational age ≤32 weeks. Respir Med 107 (2013), 1966–1976.
26. Fok, T.F., Lam, K., Dolovich, M., Ng, P.C., Wong, W., Cheung, K.L., et al. Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Archs Dis Childh Fetal Neonata Ed 80 (1999), F203–F208.
27. Cole, C.H., Colton, T., Shah, B.L., Abbasi, S., MacKinnon, B.L., Demissie, S., et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 340 (1999), 1005–1010.
28. Merz, U., Kusenbach, G., Hausler, M., Peschgens, T., Hornchen, H., Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Biol Neonate 75 (1999), 46–53.
29. Jonsson, B., Eriksson, M., Soder, O., Broberger, U., Lagercrantz, H., Budesonide delivered by dosimetric jet nebulization to preterm very low birthweight infants at high risk for development of chronic lung disease. Acta Paediatr 89 (2000), 1449–1455.
30. Zimmerman, J.J., Gabbert, D., Shivpuri, C., Kayata, S., Miller, J., Ciesielski, W., Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med 1 (2000), 140–145.
31. Jangaard, K.A., Stinson, D.A., Allen, A.C., Vincer, M.J., Early prophylactic inhaled beclomethasone in infants less than 1250 g for the prevention of chronic lung disease. Paediatr Child Health 7 (2002), 13–19.
32. Bassler, D., Halliday, H.L., Plavka, R., Hallman, M., Shinwell, E.S., Jarreau, P.H., et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 373 (2015), 1497–1506.
33. Shah, V.S., Ohlsson, A., Halliday, H.L., Dunn, M., Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev, 5, 2012 CD001969.
34. Onland, W., Offringa, M., van Kaam, A., Late (≥7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev, 4, 2012 CD002311.
35. Slaughter, J.L., Stenger, M.R., Reagan, P.B., Jadcherla, S.R., Utilization of inhaled corticosteroids for infants with bronchopulmonary dysplasia. PloS One, 9, 2014, e106838.
36. Guaman, M.C., Gien, J., Baker, C.D., Zhang, H., Austin, E.D., Collaco, J.M., Point prevalence, clinical characteristics, and treatment variation for infants with severe bronchopulmonary dysplasia. Am J Perinatol 32 (2015), 960–967.
37. Giep, T., Raibble, P., Zuerlein, T., Schwartz, I.D., Trial of beclomethasone dipropionate by metered-dose inhaler in ventilator-dependent neonates less than 1500 grams. Am J Perinatol 13 (1996), 5–9.
38. LaForce, W.R., Brudno, D.S., Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and ventilator-dependent infants. J Pediatr 122 (1993), 285–288.
39. Arnon, S., Grigg, J., Silverman, M., Effectiveness of budesonide aerosol in ventilator-dependent preterm babies: a preliminary report. Pediatr Pulmonol 21 (1996), 231–235.
40. Pappagallo, M., Abbasi, S., Bhutani, V.K., Respiratory and systemic effects of inhaled dexamethasone on ventilator dependent preterm infants at risk for bronchopulmonary dysplasia. Ind J Pediatr 65 (1998), 273–282.
41. Denjean, A., Paris-Llado, J., Zupan, V., Debillon, T., Kieffer, F., Magny, J., et al. Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Eur J Pediatr 157 (1998), 926–931.
42. Dugas, M.A., Nguyen, D., Frenette, L., Lachance, C., St-Onge, O., Fougères, A., et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 115 (2005), e566–e572.
43. Kugelman, A., Peniakov, M., Zangen, S., Shiff, Y., Riskin, A., Iofe, A., et al. Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study. J Perinatol 37 (2017), 197–202.
44. Gal, P., Diaz, P.R., Ransom, J.L., Carlos, R.Q., Thorson, D.W., Beclomethasone for treating premature infants with bronchopulmonary dysplasia. J Pediatr 123 (1993), 490–491.
45. Beresford, M.W.; Primhak, R.; Subhedar, N.V.; Shaw, N.J., Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Archs Dis Childh Fetal Neonatal Ed 200287:F62–F63.
46. Suchomski, S.J., Cummings, J.J., A randomized trial of inhaled versus intravenous steroids in ventilator-dependent preterm infants. J Perinatol 22 (2002), 196–203.
47. Halliday, H.L., Patterson, C.C., Halahakoon, C.W., A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 107 (2001), 232–240.
48. Baveja, R.; Christou, H., Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 200630:209–218.
49. Gibson, A.T., Pearse, R.G., Wales, J.K., Growth retardation after dexamethasone administration: assessment by knemometry. Archs Dis Childh 69 (1993), 505–509.
50. Yeh, T.F., Lin, Y.J., Huang, C.C., Chen, Y.J., Lin, C.H., Lin, H.C., et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics, 101, 1998 E7.
51. O'Shea, T.M., Kothadia, J.M., Klinepeter, K.L., Goldstein, D.J., Jackson, B.G., Weaver, R.G. 3rd, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 104 (1999), 15–21.
52. Bensky, A.S., Kothadia, J.M., Covitz, W., Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 97 (1996), 818–821.
53. Stark, A.R., Carlo, W.A., Tyson, J.E., Papile, L.A., Wright, L.L., Shankaran, S., et al. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human development neonatal Research network. N Engl J Med 344 (2001), 95–101.
54. Ng, P.C., Fok, T.F., Liu, F., Lee, C.H., Ma, K.C., Wong, E., Effects of inhaled corticosteroids on systemic blood pressure in preterm infants. Biol Neonate 86 (2004), 201–206.
55. Cole, C.H., Shah, B., Abbasi, S., Demissie, S., MacKinnon, B., Colton, T., et al. Adrenal function in premature infants during inhaled beclomethasone therapy. J Pediatr 135 (1999), 65–70.
56. Bauer, J., Teufel, U., Maser-Gluth, C., Doege, C., Effects of budesonide inhalation on energy expenditure, somatic growth and salivary cortisol levels in preterm infants with chronic lung disease. Horm Res 72 (2009), 146–152.
57. Dhand, R., Basic techniques for aerosol delivery during mechanical ventilation. Respir Care 49 (2004), 611–622.
58. Mandhane, P., Zuberbuhler, P., Lange, C.F., Finlay, W.H., Albuterol aerosol delivered via metered-dose inhaler to intubated pediatric models of 3 ages, with 4 spacer designs. Respir Care 48 (2003), 948–955.
59. Fok, T.F., Monkman, S., Dolovich, M., Gray, S., Coates, G., Paes, B., et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 21 (1996), 301–309.
60. Price, D., Roche, N., Christian Virchow, J., Burden, A., Ali, M., Chisholm, A., et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 105 (2011), 1457–1466.